Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib

Leukemia Research

Volumn 29, Issue 12, 2005, Pages 1473-1477

  Krauth, Maria Theresa ^a   Bankier, Alexander ^a   Valent, Peter ^a   Kalhs, Peter ^a   Drach, Johannes ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bortezomib; Extramedullary manifestation; Multiple myeloma; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; PROTEASOME INHIBITOR;

ADULT; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CASE REPORT; DIAGNOSTIC PROCEDURE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LABORATORY TEST; MULTIPLE MYELOMA; PARAVERTEBRAL PLASMACYTOMA; PLASMACYTOMA; PRIORITY JOURNAL; REFRACTORY PERIOD; TREATMENT OUTCOME; TUMOR REGRESSION;

BORONIC ACIDS; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA; PYRAZINES; REMISSION INDUCTION; SALVAGE THERAPY; SPINAL NEOPLASMS;

EID: 27644522912     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.05.003     Document Type: Article

References (20)

1. R.A. Kyle, and S.V. Rajkumar Multiple myeloma N Engl J Med 351 2004 1860 1873
2. H. Avet-Loiseau, J.Y. Li, N. Morineau, T. Facon, C. Brigaudeau, and J.L. Harousseau Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma Blood 94 1999 2583 2589
3. T.G. Willis, and M.J. Dyer The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies Blood 96 2000 808 822
4. M. Hallek, P.L. Bergsagel, and K.C. Anderson Multiple myeloma: increasing evidence for a multistep transformation process Blood 91 1998 3 21
5. S. Seidl, H. Kaufmann, and J. Drach New insights into the pathophysiology of multiple myeloma Lancet Oncol 4 2003 557 564
6. 2 as conditioning regimen for peripheral blood progenitor cell autotransplantation in patients with newly diagnosed multiple myeloma [abstract] Blood 94 Suppl. 1 1999 713a
7. B. Barlogie, S. Jagannath, D.H. Vesole, S. Naucke, B. Cheson, and S. Mattox Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma Blood 89 1997 789 793
8. S. Singhal, J. Mehta, R. Desikan, D. Ayers, P. Roberson, and P. Eddlemon Antitumor activity of thalidomide in refractory multiple myeloma N Engl J Med 341 1999 1565 1571
9. T. Hideshima, D. Chauhan, Y. Shima, N. Raje, F.E. Davies, and Y.T. Tai Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy Blood 96 2000 2943 2950
10. J. Kaufman, and S. Lonial Multiple myeloma: the role of transplant and novel treatment strategies Semin Oncol 31 2, Suppl. 4 2004 99 105
11. B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, and E. Anaissie Treatment of multiple myeloma Blood 103 2004 20 32
12. S. Singhal, and J. Mehta Novel therapies in multiple myeloma Int J Hematol 77 2003 226 231
13. P.G. Richardson, T. Hideshima, C. Mitsiades, and K. Anderson Proteasome inhibition in hematologic malignancies Ann Med 36 2004 304 314
14. R.Z. Orlowski Bortezomib and its role in the management of patients with multiple myeloma Expert Rev Anticancer Ther 4 2004 171 179
15. B.L. Stanford, and S.D. Zondor Bortezomib treatment for multiple myeloma Ann Pharmacother 37 2003 1825 1830
16. P.G. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, and D. Irwin A phase 2 study of bortezomib in relapsed, refractory myeloma N Eng J Med 348 2003 2609 2617
17. G. Damaj, M. Mohty, N. Vey, E. Dincan, R. Bouabdallah, and C. Faucher Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center Eur J Haematol 73 2004 402 406
18. L. Rosinol, M.T. Cibeira, J. Blade, J. Esteve, M. Aymerich, and M. Rozman Extramedullary multiple myeloma escapes the effect of thalidomide Haematologica 89 2004 832 836
19. S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, and P.G. Richardson A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 2004 165 172
20. P.F. Bross, R. Kane, A.T. Farrell, S. Abraham, K. Benson, and M.E. Brower Approval summary for bortezomib for injection in the treatment of multiple myeloma Clin Cancer Res 10 2004 3954 3964